680 related articles for article (PubMed ID: 28552437)
1. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
[TBL] [Abstract][Full Text] [Related]
9. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
12. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Bird P; Bensen W; El-Zorkany B; Kaine J; Manapat-Reyes BH; Pascual-Ramos V; Witcombe D; Soma K; Zhang R; Thirunavukkarasu K
J Clin Rheumatol; 2019 Apr; 25(3):115-126. PubMed ID: 29794874
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Charles-Schoeman C; Burmester G; Nash P; Zerbini CA; Soma K; Kwok K; Hendrikx T; Bananis E; Fleischmann R
Ann Rheum Dis; 2016 Jul; 75(7):1293-301. PubMed ID: 26275429
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
